Terms: = Uterine cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR AND Treatment
29 results:
1. Functional Distinctions of Endometrial cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.
Dixit G; Pappas BA; Bhardwaj G; Schanz W; Maretzky T
Cells; 2023 Sep; 12(18):. PubMed ID: 37759450
[TBL] [Abstract] [Full Text] [Related]
2. WIF1 was downregulated in cervical cancer due to promoter methylation.
Wang Y; Yuan S; Ma J; Liu H; Huang L; Zhang F; Wang X
Acta Biochim Pol; 2023 Jun; 70(2):419-423. PubMed ID: 37306343
[TBL] [Abstract] [Full Text] [Related]
3. Paiteling induces apoptosis of cervical cancer cells by down-regulation of the E6/E7-Pi3k/Akt pathway: A network pharmacology.
Liu Y; Zheng P; Jiao T; Zhang M; Wu Y; Zhang X; Wang S; Zhao Z
J Ethnopharmacol; 2023 Apr; 305():116062. PubMed ID: 36535331
[TBL] [Abstract] [Full Text] [Related]
4. Histopathological and molecular findings in 98 cases of endometrial carcinoma: MMR, p53 and next generation sequencing.
Karabağ S; Şentürk M; Söğüt FC; Ergül ÖS; Ersoy T
Pathol Res Pract; 2023 Jan; 241():154275. PubMed ID: 36528987
[TBL] [Abstract] [Full Text] [Related]
5. Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing treatment (FST) Decision Making in Early Stage Endometrial cancer (ES-EC): A Systematic Review.
Tanos P; Dimitriou S; Gullo G; Tanos V
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269800
[TBL] [Abstract] [Full Text] [Related]
6. Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial cancer.
Choi J; Holowatyj AN; Du M; Chen Z; Wen W; Schultz N; Lipworth L; Guo X
JCO Precis Oncol; 2022 Feb; 6():e2100401. PubMed ID: 35108035
[TBL] [Abstract] [Full Text] [Related]
7. Eupatilin regulates proliferation and cell cycle of cervical cancer by regulating hedgehog signalling pathway.
Wu Z; Zou B; Zhang X; Peng X
Cell Biochem Funct; 2020 Jun; 38(4):428-435. PubMed ID: 31926121
[TBL] [Abstract] [Full Text] [Related]
8. The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1.
Xu J; Wang H; Wang H; Chen Q; Zhang L; Song C; Zhou Q; Hong Y
Hereditas; 2019; 156():11. PubMed ID: 31007650
[TBL] [Abstract] [Full Text] [Related]
9. Bcl-2 inhibitors enhance FGFR inhibitor-induced mitochondrial-dependent cell death in fgfr2-mutant endometrial cancer.
Packer LM; Stehbens SJ; Bonazzi VF; Gunter JH; Ju RJ; Ward M; Gartside MG; Byron SA; Pollock PM
Mol Oncol; 2019 Apr; 13(4):738-756. PubMed ID: 30537101
[TBL] [Abstract] [Full Text] [Related]
10. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
Liu Y; Weber Z; San Lucas FA; Deshpande A; Jakubek YA; Sulaiman R; Fagerness M; Flier N; Sulaiman J; Davis CM; Fowler J; Starks D; Rojas-Espaillat L; Lazar AJ; Davies GE; Ehli EA; Scheet P
Gynecol Oncol; 2018 Nov; 151(2):243-249. PubMed ID: 30194005
[TBL] [Abstract] [Full Text] [Related]
11. Endometrial cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
[TBL] [Abstract] [Full Text] [Related]
12. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in fgfr2
Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
[TBL] [Abstract] [Full Text] [Related]
13. Targeting fibroblast growth factor pathways in endometrial cancer.
Winterhoff B; Konecny GE
Curr Probl Cancer; 2017; 41(1):37-47. PubMed ID: 28041631
[TBL] [Abstract] [Full Text] [Related]
14. Second-line dovitinib (TKI258) in patients with fgfr2-mutated or fgfr2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
[TBL] [Abstract] [Full Text] [Related]
15. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Stelloo E; Bosse T; Nout RA; MacKay HJ; Church DN; Nijman HW; Leary A; Edmondson RJ; Powell ME; Crosbie EJ; Kitchener HC; Mileshkin L; Pollock PM; Smit VT; Creutzberg CL
Mod Pathol; 2015 Jun; 28(6):836-44. PubMed ID: 25720322
[TBL] [Abstract] [Full Text] [Related]
16. A nontoxic concentration of cisplatin induces autophagy in cervical cancer: selective cancer cell death with autophagy inhibition as an adjuvant treatment.
Leisching G; Loos B; Botha M; Engelbrecht AM
Int J Gynecol Cancer; 2015 Mar; 25(3):380-8. PubMed ID: 25695544
[TBL] [Abstract] [Full Text] [Related]
17. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Powell MA; Sill MW; Goodfellow PJ; Benbrook DM; Lankes HA; Leslie KK; Jeske Y; Mannel RS; Spillman MA; Lee PS; Hoffman JS; McMeekin DS; Pollock PM
Gynecol Oncol; 2014 Oct; 135(1):38-43. PubMed ID: 25019571
[TBL] [Abstract] [Full Text] [Related]
18. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
[TBL] [Abstract] [Full Text] [Related]
19. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.
Gadducci A; Sergiampietri C; Guiggi I
Gynecol Endocrinol; 2013 Sep; 29(9):811-6. PubMed ID: 23767831
[TBL] [Abstract] [Full Text] [Related]
20. FGF receptors: cancer biology and therapeutics.
Katoh M; Nakagama H
Med Res Rev; 2014 Mar; 34(2):280-300. PubMed ID: 23696246
[TBL] [Abstract] [Full Text] [Related]
[Next]
